Elite Pharmaceuticals, Inc.
ELTP
$0.26
$0.00-1.08%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 56.67M | 44.87M | 43.41M | 13.92M | -10.82M |
| Total Depreciation and Amortization | 2.00M | 2.02M | 2.05M | 2.03M | 2.07M |
| Total Amortization of Deferred Charges | 14.00K | 14.00K | 14.00K | 14.00K | 14.00K |
| Total Other Non-Cash Items | -21.40M | 4.76M | 7.63M | 29.70M | 49.15M |
| Change in Net Operating Assets | -18.24M | -27.92M | -34.58M | -22.93M | -21.33M |
| Cash from Operations | 19.04M | 23.75M | 18.52M | 22.73M | 19.09M |
| Capital Expenditure | -1.52M | -925.60K | -1.28M | -1.08M | -1.06M |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 110.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Investing | -1.52M | -925.60K | -1.28M | -1.08M | -954.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -629.00K | -4.64M | -4.68M | -4.75M | -4.80M |
| Issuance of Common Stock | 322.70K | 318.70K | 259.50K | 169.30K | 19.30K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -306.20K | -4.32M | -4.42M | -4.58M | -4.78M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.22M | 18.50M | 12.82M | 17.08M | 13.35M |